vs
1ST SOURCE CORP（SRCE）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是1ST SOURCE CORP的1.1倍（$127.1M vs $113.1M），再鼎医药同比增速更快（17.1% vs 8.7%），1ST SOURCE CORP自由现金流更多（$58.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 7.8%）
第一来源公司（1st Source Corporation）是总部位于美国印第安纳州南本德的金融服务企业，旗下运营第一来源银行，在印第安纳州和密歇根州拥有81家分支机构，其专业金融团队为飞机、卡车、工程设备提供融资服务，同时还通过第一来源保险板块提供各类保险产品及相关服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
SRCE vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.1倍
$113.1M
营收增速更快
ZLAB
高出8.4%
8.7%
自由现金流更多
SRCE
多$84.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
7.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $113.1M | $127.1M |
| 净利润 | $40.0M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 45.4% | -54.6% |
| 净利率 | 35.3% | — |
| 营收同比 | 8.7% | 17.1% |
| 净利润同比 | 6.5% | — |
| 每股收益（稀释后） | $1.63 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SRCEZLAB
| Q1 26 | $113.1M | — | ||
| Q4 25 | $110.8M | $127.1M | ||
| Q3 25 | $110.7M | $115.4M | ||
| Q2 25 | $108.2M | $109.1M | ||
| Q1 25 | $104.0M | $105.7M | ||
| Q4 24 | $97.8M | $108.5M | ||
| Q3 24 | $97.9M | $101.8M | ||
| Q2 24 | $97.3M | $100.1M |
净利润SRCEZLAB
| Q1 26 | $40.0M | — | ||
| Q4 25 | $41.1M | — | ||
| Q3 25 | $42.3M | $-36.0M | ||
| Q2 25 | $37.3M | $-40.7M | ||
| Q1 25 | $37.5M | $-48.4M | ||
| Q4 24 | $31.4M | — | ||
| Q3 24 | $34.9M | $-41.7M | ||
| Q2 24 | $36.8M | $-80.3M |
毛利率SRCEZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率SRCEZLAB
| Q1 26 | 45.4% | — | ||
| Q4 25 | — | -54.6% | ||
| Q3 25 | 49.7% | -42.3% | ||
| Q2 25 | 44.5% | -50.3% | ||
| Q1 25 | 45.8% | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | 46.3% | -66.6% | ||
| Q2 24 | 49.1% | -76.0% |
净利率SRCEZLAB
| Q1 26 | 35.3% | — | ||
| Q4 25 | 37.1% | — | ||
| Q3 25 | 38.2% | -31.2% | ||
| Q2 25 | 34.5% | -37.3% | ||
| Q1 25 | 36.1% | -45.8% | ||
| Q4 24 | 32.1% | — | ||
| Q3 24 | 35.7% | -40.9% | ||
| Q2 24 | 37.8% | -80.2% |
每股收益（稀释后）SRCEZLAB
| Q1 26 | $1.63 | — | ||
| Q4 25 | $1.67 | $-0.05 | ||
| Q3 25 | $1.71 | $-0.03 | ||
| Q2 25 | $1.51 | $-0.04 | ||
| Q1 25 | $1.52 | $-0.04 | ||
| Q4 24 | $1.27 | $-0.09 | ||
| Q3 24 | $1.41 | $-0.04 | ||
| Q2 24 | $1.49 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $715.5M |
| 总资产 | $9.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SRCEZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M |
股东权益SRCEZLAB
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $715.5M | ||
| Q3 25 | $1.2B | $759.9M | ||
| Q2 25 | $1.2B | $791.7M | ||
| Q1 25 | $1.2B | $810.8M | ||
| Q4 24 | $1.1B | $840.9M | ||
| Q3 24 | $1.1B | $667.7M | ||
| Q2 24 | $1.0B | $704.2M |
总资产SRCEZLAB
| Q1 26 | $9.1B | — | ||
| Q4 25 | $9.1B | $1.2B | ||
| Q3 25 | $9.1B | $1.2B | ||
| Q2 25 | $9.1B | $1.2B | ||
| Q1 25 | $9.0B | $1.2B | ||
| Q4 24 | $8.9B | $1.2B | ||
| Q3 24 | $8.8B | $985.3M | ||
| Q2 24 | $8.9B | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $59.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $58.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 51.4% | -21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.48× | — |
| 过去12个月自由现金流最近4个季度 | $361.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流SRCEZLAB
| Q1 26 | $59.1M | — | ||
| Q4 25 | $223.1M | $-26.0M | ||
| Q3 25 | $51.0M | $-32.0M | ||
| Q2 25 | $44.9M | $-31.0M | ||
| Q1 25 | $71.8M | $-61.7M | ||
| Q4 24 | $193.9M | $-55.8M | ||
| Q3 24 | $68.4M | $-26.8M | ||
| Q2 24 | $50.0M | $-42.2M |
自由现金流SRCEZLAB
| Q1 26 | $58.1M | — | ||
| Q4 25 | $213.0M | $-26.7M | ||
| Q3 25 | $47.3M | $-35.0M | ||
| Q2 25 | $43.0M | $-33.9M | ||
| Q1 25 | $69.3M | $-63.2M | ||
| Q4 24 | $181.5M | $-58.4M | ||
| Q3 24 | $66.7M | $-28.2M | ||
| Q2 24 | $46.4M | $-42.9M |
自由现金流率SRCEZLAB
| Q1 26 | 51.4% | — | ||
| Q4 25 | 192.2% | -21.0% | ||
| Q3 25 | 42.7% | -30.4% | ||
| Q2 25 | 39.8% | -31.1% | ||
| Q1 25 | 66.6% | -59.9% | ||
| Q4 24 | 185.5% | -53.8% | ||
| Q3 24 | 68.1% | -27.7% | ||
| Q2 24 | 47.7% | -42.9% |
资本支出强度SRCEZLAB
| Q1 26 | 0.9% | — | ||
| Q4 25 | 9.1% | 0.5% | ||
| Q3 25 | 3.4% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 2.4% | 1.5% | ||
| Q4 24 | 12.6% | 2.4% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 3.7% | 0.7% |
现金转化率SRCEZLAB
| Q1 26 | 1.48× | — | ||
| Q4 25 | 5.42× | — | ||
| Q3 25 | 1.21× | — | ||
| Q2 25 | 1.20× | — | ||
| Q1 25 | 1.91× | — | ||
| Q4 24 | 6.17× | — | ||
| Q3 24 | 1.96× | — | ||
| Q2 24 | 1.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SRCE
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
